Following on from her first article investigating how physicians make decisions, Theano Anastasopoulou explains how cognitive biases can influence the ways new drugs are promoted.
In the first of two articles, Theano Anastasopoulou uses behavioural economics to understand and investigate how physicians make decisions and thereby improve the take-up of new medicines.
It has been nearly two years since Pfizer’s sickle cell disease (SCD) therapy Oxbryta was approved in the UK, but patients will now be able to access the treatment after a
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.